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Imaging methods for pulmonary sarcoidosis
Abstract
Sarcoidosis is a chronic systemic granulomatous disease of unknown etiology. In more than 90% of patients with diagnosed 
sarcoidosis, mediastinal and hilar lymph nodes are affected. The objective of this paper is to discuss the most important chest 
imaging methods in pulmonary sarcoidosis. A chest X-ray remains the method of choice at both the diagnostic stage and during 
follow-up of the disease progress. High-resolution computed tomography allows for a more thorough description of lesions in 
terms of their location. Research demonstrates the superiority of FDG PET over both aforementioned techniques in the assessment 
of active inflammatory lesions. Magnetic resonance imaging is currently being used in diagnosing cardiac sarcoidosis. Although 
EBUS constitutes the basic diagnostic tool, the invasiveness of the method results in it not being used when monitoring the 
activity of the disease.
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Introduction 
Sarcoidosis is a chronic granulomatous dis-
ease of unknown etiology [1]. In more than 90% of 
patients with diagnosed sarcoidosis, mediastinal 
and hilar lymph nodes are affected [2, 3]. The 
diagnosis is based on the evaluation of clinical, 
radiological, and histopathological features [7]. 
The objective of this paper is to discuss the most 
important chest imaging methods in pulmonary 
sarcoidosis and to determine their role in the 
process of diagnosing the disease and monitoring 
its activity. 
Conventional X-ray
The method of choice which should be ap-
plied in each and every patient with a clinical 
suspicion of sarcoidosis is a conventional X-ray 
[8]. Its unquestionable advantages include its 
wide availability and low cost. Despite the de-
velopment of other techniques, X-ray imaging 
remains the first examination recommended in 
the diagnostic procedure, and a gold standard in 
monitoring the activity of the already diagnosed 
disease [8]. It is recommended to apply relevant 
scales in order to systematise and standardise 
X-ray images. One of the best-known scales is 
the one proposed by Scadding/Siltzbach in 1961 
in which patients were classified according to 
one of four groups based on lesions visible in 
the chest X-ray (i.e. enlarged hilar lymph nodes, 
the presence of parenchymal infiltrations, and 
features of fibrosis) [9]. The first group included 
patients with isolated hilar lymphadenopathy; 
the second — subjects with accompanying pa-
renchymal infiltrations; the third — subjects 
without lymphadenopathy, but with lesions in 
the lung parenchyma; the fourth — patients with 
fibrotic lesions. On the basis of the group of pa-
tients (n = 136), Scadding rated the incidence of 
individual groups in the population of patients 
with sarcoidosis and the probability of sponta-
neous remission in each of them [9]. This scale 
was accepted and has been widely used to date. 
Another classification method, which was applied 
in the analysis of pneumoconiosis and adapted by 
Muers  et al., consists of the division of both lung 
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lobes into zones and in the evaluation of the pro-
fusion of individual types of lesions in the zones, 
specifically reticulonodular changes, masses, 
confluents, and fibrosis [10, 11]. The chest X-ray 
and the pulmonary function test (PFT) consti-
tute the main tools for monitoring the activity of 
sarcoidosis. Boros et al. retrospectively analyzed 
the results of functional tests in 830 patients 
with diagnosed sarcoidosis. They analyzed them 
based on the stage that they were in determined 
by the Scadding/Siltzbach classification of chest 
X-ray [12]. Despite the parenchymal changes 
visible in the chest X-ray in about three-quarters 
of patients (stages II–IV), only 7% had a restric-
tion in lung volume. At each stage (according to 
Scadding/Siltzbach), the lung transfer factor for 
carbon monoxide was impaired and static lung 
compliance was reduced [12]. Despite an estab-
lished position which identifies X-ray imaging as 
a tool for monitoring the disease, the discussion 
devoted to decision making with reference to the 
onset of therapy based exclusively on the basis 
of radiological changes without accompanying 
lung function disorders is still ongoing. Pietinal-
ho et al., in their study of patients with recently 
diagnosed sarcoidosis that had no deviations in 
the functional tests, applied a 3 months’ therapy 
with prednisone, which was followed by inhaled 
budesonide for 15 months. They demonstrated 
that patients, who at the onset of the therapy had 
stage II/III sarcoidosis and received treatment, 
experienced specific benefits in terms of FVC 
and DLCO 5 years after the study. Furthermore, 
they required glucocorticosteroid therapy much 
later than when compared to the placebo group 
[5]. Considering the possible side effects of the 
therapy, it is recommended to exercise caution 
when deciding about the beginning and/or con-
tinuation of treatment based exclusively on the 
advancement of the disease as evaluated in the 
chest X-ray. Figure 1 presents typical conventional 
chest X-ray picture of stage II sarcoidosis. 
High resolution computed tomography
A method that has become much more acces-
sible is computed tomography. High-resolution 
computed tomography (HRCT), which is a me-
thod of choice in the evaluation of interstitial 
diseases, demonstrates a considerable superiority 
over the CT with contrast in the detection and 
evaluation of even subtle lesions in lung paren-
chyma [14]. Routine diagnostic protocols make 
use of thin-layer scans, from 1 to 1.5–2 mm [15]. 
In the past, the “so-called” sequential HRCT scans 
were used where layers were visualized every 
10 mm from the apex of the lung to its base at full 
inspiration. As a result, as much as 90% of the 
lung was not seen on imaging. Thanks to advan-
ced technical devices (multiple detector compu-
ted tomography), the rotation time necessary to 
generate the image has been shortened to 0.28–0.5 
seconds (depending on the type of the apparatus). 
The use of spiral acquisition enhanced the scan 
sensitivity and minimised respiratory and pulsa-
tory artefacts [15, 16, 17]. According to the 1999 
ATS/ERS/WASOG guidelines which are still valid, 
there are three indications to perform a CT scan: 
a) if there are no lesions in the X-ray, but there 
is a clinical suspicion of sarcoidosis (stage 0); 
b) if there are atypical clinical or radiological 
symptoms; and c) in order to diagnose possible 
complications [1]. There are two typical findings 
in sarcoidosis in HRCT. Firstly, there is hilar and 
mediastinal lymphadenopathy which is most 
frequently bilateral and symmetrical. Secondly, 
there are nodules (both micronodules [2–4 mm in 
diameter] and macronodules (diameter ≥ 5 mm)] 
which can be located along bronchovascular bun-
dles, interlobular septi, interlobar fissures, and in 
the subpleural region (Figure 2) [18]. In advanced 
stages, the features of fibrosis are visible and can 
include honeycombing, architectural distortion, 
traction bronchiectasis, and/or volume loss. Most 
frequently, lesions in sarcoidosis demonstrate 
predilection to the upper and middle fields [18]. 
Figure 1. Chest X-ray of the patient with stage II sarcoidosis. Enlarged 
bilateral hilar lymph nodes, widening of mediastinum and bilateral 
nodular shadows spreading from perihilar regions to the lung periphery
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The increasingly widespread application of the 
HRCT scan is associated with better-known ra-
diological characteristics of sarcoidosis. Cases of 
histopathologically confirmed sarcoidosis with 
atypical manifestations in the HRCT scan are 
becoming more and more frequent. Sarcoidosis 
has been dubbed “the great imitator”, just like 
tuberculosis before it [19, 20]. More and more 
authors present cases of patients with new CT 
patterns [21]. Radiological manifestations less 
frequently encountered in sarcoidosis but seen 
on HRCT include unilateral or isolated lympha-
denopathy, parenchymal infiltrations in the form 
of conglomerate masses, single nodules larger 
than 1 cm, confluent alveolar opacities (alveolar 
sarcoid pattern), and cavernous changes [18]. An 
interesting symptom is that of granulomatous 
nodules coalescing together to form larger ones, 
which was described for the first time by Nakat-
su et al. [21]. Bigger nodules are surrounded by 
smaller satellite nodules forming a structure re-
sembling stars forming a galaxy, hence the galaxy 
symptom mentioned by the authors. In the study, 
this symptom was found in 16 out of 59 subjects. 
The 3-mm collimation was used for the evaluation 
of the larger nodules (instead of conventionally 
used 1–2 mm layer) which, in the authors’ opi-
nion, had a positive effect on the visualisation of 
peripheral micronodules, bronchioles, and bran-
ches thereof [21]. Another relatively new image of 
sarcoidosis in HRCT is the “sarcoid cluster sign” 
which was first described by Herráez Ortega. This 
sign is characterised by the accumulation of small 
punctiform nodules on the periphery of the lungs 
[22]. However, both “galaxy” and “cluster” signs 
can be seen in pulmonary TB and silicosis as well 
(Figure 3) [23–25].
According to the authors, the majority of such 
lesions are arranged in circular groups and are not 
located directly in subpleural peripheral regions 
of the upper and middle fields of the lungs [22]. 
Other patterns visible in HRCT have been also 
described such as “reversed halo” ring-shaped 
areas of consolidation with a central ground-glass 
attenuation [26–29]. Besides the precise assess-
ment of the profusion of interstitial lesions, HRCT 
also indirectly allows to assess the prognosis for 
patients suffering from sarcoidosis by differentia-
ting between reversible and irreversible lesions 
[30]. Lesions such as micronodules, nodules, or 
peribronchovascular thickening can withdraw 
spontaneously or under treatment. On the other 
hand, consolidations, ground-glass opacification, 
or linear opacities are characterised by variable 
reversibility. Irreversible lesions include architec-
tural distortion, bronchiectasis, honeycombing, 
and emphysematous bullae (Figure 4) [31]. The 
role of HRCT in diagnosing sarcoidosis, particu-
larly in cases which are difficult to diagnose, is 
currently broadly recognised. There is an ongo-
ing discussion regarding the role of computed 
tomography in the monitoring of the activity of 
Figure 2. Chest high resolution computed tomography of the patient 
with stage II sarcoidosis. Enlarged hilar and subcarinal lymph nodes, 
disseminated high density nodules in both middle lung areas, with 
peribronchial and subpleural distribution
Figure 3. Chest high resolution computed tomography showing coale-
scent nodules forming larger irregular nodes — “galaxy sign”
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the disease. This discussion is attempting to de-
termine whether it should be repeated routinely 
in every patient, whether it should be applied 
only in the case of more advanced lesions visi-
ble on an X-ray, and whether it should be used 
in the presence of functional disorders. Ziora  et 
al. analysed a group of patients who would have 
fallen into group 1 according to the Scadding sca-
le. After examining these patients by HRCT, they 
assigned them to two separate subgroups: patients 
with lesions in pulmonary parenchyma, and 
patients without parenchymal lesions [32]. Both 
groups underwent regular functional testing and 
X-ray scans. During a 2-year long observation, no 
statistically significant difference was observed 
between the functional test results. Moreover, the 
share of patients with radiological stabilisation, 
progression, or improvement was not different 
in both groups [32]. Numerous studies have de-
monstrated the superiority of HRCT in detecting 
lesions corresponding to fibrosis and in diagno-
sing more advanced stages of the disease. Chest 
X-ray scans revealed fibrosis in 5–10%, whereas 
CT scans resulted in such changes being descri-
bed in as many as 20–50% of patients [33–35]. 
Currently, there are no clear data which would 
allow to determine whether repeated HRCT scans 
in patients suffering from sarcoidosis have any 
effect on making therapeutic decisions. Levy et al. 
recommend repeated HRCT scans if the clinical 
image changes or complications are suspected [36 
37]. Unlike X-ray scans, some lesions visible in 
HRCT demonstrate a relationship with pulmonary 
function disorders [38–40]. Drent et al. demonstra-
ted correlations between features visible in HRCT 
such as thickening of the bronchovascular bundle, 
intraparenchymal nodules, septal and non-septal 
lines, or focal pleural thickening on one hand, and 
results of respiratory functional tests on the other 
[38]. However, such a relationship has not been 
demonstrated for consolidations, ground-glass 
opacifications, or enlargement of lymph nodes. 
Furthermore, the study also demonstrated the 
superiority of the HRCT scan over a conventional 
X-ray scan in terms of their relationship to the 
respiratory function parameters of the lungs [38].
Gallium-67 scintigraphy
Another imaging method used in sarcoidosis 
is Gallium-67 scintigraphy (Ga-67), albeit less 
and less frequently so. Its sensitivity in detecting 
pulmonary sarcoidosis ranges from 60 to 90% 
[41, 42]. For patients suffering from sarcoidosis, 
two gallium uptake patterns are characteristically 
used known as lambda and panda, and are named 
as such because of their shapes [43]. The lamb-
da pattern comprises the gallium uptake in the 
parahilar and infrahilar lymph nodes along with 
the paratracheal lymph nodes on the right-hand 
side [43]. The panda pattern is associated with 
a  symmetrical uptake in parotid and lacrimal 
glands, as well as in submandibular and sublin-
gual salivary glands. The constellation of the 
lambda and panda pattern uptake is recognised 
as very characteristic for sarcoidosis [17, 44]. 
Gallium-67 scintigraphy is more sensitive than 
an X-ray scan and can be applied for the evalu-
ation of the staging of the disease activity, for the 
assessment of treatment results, and for the pre-
diction of relapses. However, a more widespread 
application of this method is limited due to its 
restricted availability, cost, exposure to radiation, 
and duration [43].
Scintigraphy with other tracers
It is also possible to use scintigraphy with 
other tracers. Somatostatin receptor (SR) scin-
tigraphy is based on the uptake of octreotide 
derivatives, such as 99mTc-octreotide or other 
somatostatin derivatives, by somatostatin subtype 
2 receptors. The application of this method affec-
ted therapeutic decisions of Piotrowski et al., who 
in their study compared the predictive value of 
scintigraphy with 99mTc-octreotide and biomar-
kers (SACE, CRP, markers of calcium metabolism, 
lymphocytes in BALF, 8-isoprostane in exhaled 
Figure 4. Lung fibrosis in sarcoidosis. Severe architectural distortion
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breath condensate) [45]. The authors observed 
the uptake in the area of pulmonary parenchyma 
in patients who had been previously disqualified 
from treatment. The attempted therapy in such 
patients was associated with a partial regression 
of interstitial changes. However, it was decided 
to terminate the treatment in patients subjected 
to long-term therapy with glucocorticosteroids 
who also had a negative scintigraphy result. In 
relation to the biomarkers, a significantly higher 
level of EBC 8-IP was demonstrated in patients 
with a positive uptake in scintigraphy as compa-
red to patients with a negative scintigraphy result. 
Furthermore, a positive correlation between the 
uptake ratio and the level of SACE in the group 
of patients with a positive scintigraphy result was 
observed [45]. French authors compared gallium 
scintigraphy with SRS in a group of 18 patients 
with recognized sarcoidosis. SRS appears to be 
accurate and contributes to a better evaluation 
of organ involvement in sarcoidosis patients, 
especially those treated with corticosteroids [46]. 
Single-photon emission computed tomography
The image of classical scintigraphy is ob-
tained by projecting a three-dimensional object 
onto a plane. This technique is extended by the 
use of several gamma cameras rotating around 
the patient, which allows to obtain an image of 
selected layers. This method, referred to as single-
photon emission computed tomography (SPECT), 
was applied by Vis et al. [47]. The SPECT/CT scan 
was performed in a group of 10 patients after 
the administration of technetium-99m(99mTc)
-labelled infliximab. The patients demonstrated 
a correlation between the radiomarker accumu-
lation in SPECT and the lab parameters (sIL-2R, 
ACE level in serum, ACE Z-score, CD4/CD8 level 
in BAL), functional test disorders, as well as the 
PET scan with fluorodeoxyglucose. The study 
demonstrated variable selective accumulation 
of the radiomarker in SPECT, which correlated 
positively with the lab markers and negatively 
with the pulmonary function, as well as with the 
PET scan [47]. A similar result was also obtained 
by — without limitations — Galli  et al., who 
demonstrated a negative correlation between the 
uptake of 99mTc-labelled infliximab and the acti-
vity measured in the PET scan. The scan with the 
application of 99mTc-labelled infliximab with the 
TNF alpha inhibitor may be used in the future to 
select groups of patients where this therapy will 
be effective. However, further research into this 
subject is required [48].
Positron-emission tomography
Another study in the field of nuclear medi-
cine is positron-emission tomography (PET). Si-
multaneous use of computed tomography allows 
to shorten the duration of the scan and additio-
nally improve the accuracy of descriptions of 
anatomical changes detected (PET/CT) [49]. The 
most commonly used marker is 18F-FDG, which 
is a glucose analogue. Transported through the 
cell membrane inside the cell, it is subjected to 
phosphorylation by hexokinase. Consequently, 
a molecule of 18F-FDG-6 phosphate is formed 
and it is not metabolised any further. The accu-
mulation of macrophages exhibiting increased 
metabolism in the area of sarcoid granulomas 
causes an uptake of the administered marker 
by glucose transporters GLUT-1 and GLUT 3 
[50]. The superiority of 18F-FDG PET/CT over 
Gallium-67 scintigraphy was demonstrated by 
Braun et al. in their study. They confirmed the 
very high sensitivity of the former in detecting 
active foci within the chest reaching 100%, as 
compared to 71% when scintigraphy is applied 
[49]. In addition, the advantages of FDG-PET 
include having 3 times lower radiation dose and 
shorter time of procedure [51].
The research points to a  good correlation 
between an X-ray and PET scan in the case of 
higher stages of sarcoidosis according to the 
Scadding scale [52]. A chest X-ray showing no 
lesion, which stands for stage 0 in this classifi-
cation, does not exclude a positive result of the 
PET scan. In the study of Mostard et al., in 27% 
of patients with no symptoms in the chest X-ray, 
a marker uptake was detected. In advanced stage 
4 patients, activity was also visible in the PET 
scan for the majority of subjects (88%) [51]. The 
study also compared HRCT (on the basis of the 
score proposed by Oberstein) with images obta-
ined in PET scans (occurrence/non-occurrence 
of changes). In this case, patients with the score 
0, according to Oberstein, did not have any 
changes visible in the PET scan. Conversely, in 
subjects where HRCT scan revealed features of 
fibrosis, the activity was frequently visible in 
the PET scan. This may be indicative of a still 
active and potentially reversible inflammatory 
process [52]. The selection of patients in which 
the inflammatory process is still ongoing despite 
fibrosis having been found may allow clinicians 
to choose the optimum treatment in this group 
of patients. PET can be applied in the diagnostic 
procedure of the disease; it allows to detect active 
inflammatory lesions in patients with symptoms, 
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even if other diagnostic methods give negative 
results. PET also identifies the best locations for 
biopsy. It is used for monitoring the activity of 
the disease, and diffuse parenchymal infiltrations 
detected in this scan allow to predict further 
loss of the pulmonary activity [53, 54]. Sobic-
Saranovic et al. demonstrated that in a group 
of 90 patients subjected to 18F-FDG PET/CT 
scans, 81% of them had decisions regarding fur-
ther treatment made based on the scan result. In 
the majority of patients in which an increased 
marker uptake was observed in the PET scan, 
the previously administered dosage of glucocor-
ticosteroids was increased or a new medication 
was used. On the other hand, patients with 
a negative scan result had their dosage reduced 
or the medications were discontinued altogether 
[55]. PET can be helpful in deciding whether 
patients with severe sarcoidosis should receive 
biological treatment. In the study by Vorselaars et 
al., a PET scan was performed prior to the onset 
of therapy and then again after 26 weeks [56]. 
The second follow-up scan revealed a reduction 
of the standardised uptake value in the region 
of mediastinum by 2.97 (P < 0.0001), and in the 
region of lung parenchyma by 3.93 (p < 0.0001) 
as compared to the output SUV values. The higher 
the SUV values were prior to the administration 
of infliximab, the greater the improvement was 
in terms of the FVC values observed after treat-
ment [56]. 
The role that PET can play in the evaluation 
of the activity of the disease in the future is po-
inted to by the study comparing the serological 
markers of the activity of the disease used so far, 
such as ACE and soluble interleukin 2 receptor 
[57]. In a  retrospective study, 36 patients with 
recently diagnosed symptomatic disease had 
a PET scan performed and their levels of ACE and 
sIL-2R were measured. F-FDG PET was positive in 
as many as 34 out of 36 patients (94%), elevated 
levels of ACE were observed in 13 patients (36%), 
and increased sIL-2R in 17 (47%) [57].
Additional benefits offered by a PET scan 
also include the extent of the examination which 
covers the entire body and can sometimes allow 
to find sarcoid foci in other organs. This scan can 
constitute an alternative for patients with suspec-
ted cardiac sarcoidosis in whom an MRI scan 
cannot be performed (e.g. due to the presence of 
a pacemaker or ICD) [53].
Unfortunately, the uptake of 18F-FDG oc-
curs in sarcoid as well as neoplastic lesions. 
Therefore, this examination is not suitable for 
differentiating between sarcoidosis and neo-
plasms. A group of Japanese researchers raised 
the subject of using another marker, 18F-FMT 
(Fluorine-18-α-Methyltyrosine) [58]. The study 
covered a group of 24 patients with sarcoidosis 
that also had an additional suspicion of a neo-
plastic process occurring. The control group 
included patients with diagnosed lung cancer. 
In all the subjects from the examined group, the 
uptake of 18F-FDG in lymph nodes was observed, 
whereas 18F-FMT was not accumulated in them. 
In extranodal organs, such as the liver, spleen, 
and bones, the PET scan result was positive if 
the former marker was used and negative with 
the latter. The neoplastic disease was not dia-
gnosed in any of the study subjects [58]. The 
mean standardised uptake values (SUV) in the 
examined group for 18F-FDG and 18F-FMT were 
5.01 ± 2.15 and 0.77 ± 0.24 respectively, whe-
reas in the control group consisting of patients 
suffering from the neoplastic disease the values 
were 6.34 ± 2.52 for 18F-FDG and 1.54 ± 0.82 for 
18F-FMT. On the basis of these results, the authors 
concluded that the additional use of 18F-FMT 
besides 18F-FDG may facilitate the differentiation 
between sarcoid and malignant changes [58]. 
Like is the case with Gallium-67 scintigraphy, the 
common use of PET and PET/CT scans is limited 
due to their limited availability and high costs. 
Figures 5 and 6 present PET results of patients 
with sarcoidosis.
Figure 5. PET-CT axial view showing increased 18F-FDG uptake in 
both hilar and subcarinal lymph nodes. The patient was suspected 
of lymphoma, after endobronchial ultrasound (EBUS) transbronchial 
needle biopsy sarcoidosis was confirmed
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Magnetic resonance imaging
Magnetic resonance imaging (MRI) is a rec-
ognised imaging method in the diagnostic pro-
cedure of cardiac sarcoidosis and in evaluating 
changes in the structure of bones or in the 
central nervous system, but it is rarely applied 
for the evaluation of the lung parenchyma due 
to the limitations of this method associated 
with the presence of air in the lung tissue and 
the physiological motion of the chest (cardiac 
pulsation, respiration) [17, 59–61]. Most stud-
ies have demonstrated the superiority of HRCT 
over MRI in the evaluation of interstitial lesions 
[17]. Brady et al., who used the technique of late 
enhancement in magnetic resonance imaging in 
their work, obtained comparable results when 
using HRCT and MRI in the description of lesions 
suggestive of fibrosis [62]. Consistency between 
MRI and HRCT in the diagnosis of pulmonary 
sarcoidosis was also confirmed by Chung  et al., 
who evaluated images in terms of the presence 
of interstitial changes, reticulations, nodules, 
and condensations according to a 3-point scale 
in the division into lobes. Furthermore, they 
noticed that a better correlation between the 
scans related to the upper lobes [63]. In relation 
to lymphadenopathy, MRI is a technique demon-
strating a similar value to computed tomography 
in detecting enlargement of hilar and mediastinal 
lymph nodes. Nevertheless, MRI facilitates the 
evaluation of the extent of lymphadenopathy 
as it is differentiated better from the vascular 
system of the lungs [64]. Chung et al., referred 
to above, analysed MRI scans performed in the 
heart examination protocol and noticed that 
some patients with sarcoidosis had lymph nodes 
with a  specific appearance: a hypo-intensive 
signal inside and a hyper-intensive rim. This 
symptom was called a dark lymph node sign by 
the authors. Retrospectively, it occurred in 49% 
of patients from the examined group [65]. New 
signs being described in MRI scans give hope 
for better characteristics of sarcoidosis based on 
MRI and potentially, for a more common use of 
this method in the future. 
Endoscopic ultrasonography
Many studies assessing the possibility of 
using endoscopic ultrasonography in the evalu-
ation of lymph nodes in patients suffering from 
sarcoidosis have been conducted in recent years. 
EBUS/EUS already enjoys an established position 
in the diagnosis of sarcoidosis [4–6]. EBUS allows 
to evaluate 2R, 4R lymph nodes on the right-hand 
side, 2L, 4L lymph nodes on the left-hand side, 
as well as paratracheal and subcarinal regions 
(group 7). Additionally, EBUS helps to access 
hilar lymph nodes (group 10) and the interlobar 
region of group 11. An EUS scan allows to exam-
ine the subcarinal region 7, the paraesophageal 
region 8, and region 9. It is also possible to access 
the paratracheal region on the left-hand side (4L), 
and to partially assess the left hilar region as 
well (10 L). A meta-analysis covering 14 studies 
(which covered 2097 subjects in total) demon-
strated a high diagnostic efficiency of this method, 
Figure 6. PET-CT coronal view. The patient with chronic sarcoidosis, 
presenting signs of radiological remission in most recent CT. PET 
was performed to exclude suspected extrathoracic manifestation of 
sarcoidosis. Increased uptake of 18F-FDG in cervical, intrathoracic 
and pelvical lymph nodes
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reaching 79%. Its sensitivity and specificity were 
estimated to be 84% and 100%, respectively [66]. 
The percentage of positive results obtained thanks 
to the EBUS-TBNA method is higher in patients 
with stage 1 than 2, which probably results from 
a higher density of granulomas in stage 1. EBUS 
allows not only to collect the material, but also 
to evaluate lymph nodes. In their study, Erol et 
al. compared the image of lymphadenopathy in 
tuberculosis and sarcoidosis [67]. Lymph nodes 
in sarcoidosis formed conglomerates more often 
than in tuberculosis and were also characterised 
by higher homoechogenicity. In tuberculosis, 
lymph nodes were more frequently oval in shape 
and more heterogenous, and their foci of necro-
sis were bigger as well. Due to the fact that both 
diseases belong to the group of granulomatous 
diseases, lymph nodes had a  similar vascular 
pattern [67]. Agrawal et al. compared inter alia 
metastatic lymph nodes with lymph nodes en-
larged due to sarcoidosis. In this case, features 
that differentiated lymph nodes in the course of 
proliferative diseases from sarcoid ones were pre-
dominantly heterogenicity, clear margins, signs 
of coagulative necrosis, and the presence of the 
central hilar structure (CHS) [68]. Regrettably, due 
to the invasiveness of this method, it cannot be 
practically used in the monitoring of the activity 
of the disease [69]. 
Transthoracic ultrasound scan
Nowadays, advanced high-resolution ultra-
sound apparatuses with facultative employment 
of colour Doppler allow to examine the mediasti-
num and the heart region. In their study, Hirche 
et al. compared the application of a transthoracic 
ultrasound scan with a conventional X-ray scan 
[70]. The use of an ultrasound scan in the evalua-
tion of mediastinal lymph nodes proved to be up 
to 90% effective. Lymph nodes in patients who 
on the basis of a chest X-ray had been assigned 
to groups 1–3 according to the Scadding score 
were particularly well visible. This is in contrast 
to group 4, in which the ultrasound visualisation 
of lymph nodes turned out to be insufficient. 
A benefit stemming from this method is the fact 
it allows for a morphological assessment of the 
lymph nodes, which is not possible based on an 
X-ray scan. In the study summary, however, the 
authors emphasise that the sensitivity of this 
method in detecting lymphadenopathy is highly 
dependent on the experience and skills of the 
operator and the class of the device [70].
Conclusion
Currently, we have observed constant prog-
ress in the field of imaging. Thanks to the devel-
opment of advanced techniques, it is possible to 
understand sarcoidosis better, to grasp its natural 
course and the effect of treatment onto the activ-
ity of the changes. A chest X-ray scan remains 
the basic examination at the stage of diagnosis, 
as well as in the subsequent monitoring of the 
disease. High-resolution computed tomography 
allows for a more precise description of lesions 
with reference to their location. Studies point to 
the superiority of FDG PET over both methods in 
the evaluation of active inflammatory changes. 
The use of other markers in PET, such as FAMPT 
for example, may be helpful in differentiating 
between sarcoid and malignant changes in the 
future. Ultimately, deciding which diagnostic 
method is best for each individual patient is 
the responsibility of the clinician. The decision 
should be made on the basis of an analysis of 
possible profits and losses considering the repeat-
ability of the results, availability of the method, 
its invasiveness, radiation exposure, cost, and 
possible influence on therapeutic decisions. It 
is worth emphasizing, that the average radiation 
dose in the case of X-ray imaging (PA and lateral 
view) ranged from 0,05–0,25 mSv, in the case of 
HRCT from 2,1–3,5 mSv, and in the case of PET 
from 7–11,5 mSv. Bearing in mind that most of 
the patients with sarcoidosis are between the 
ages 20 and 40 years old and will never require 
treatment, the decision about repeated studies 
involving a high dose of radiation should be made 
prudently [72].
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